Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735201 | 0.96 | PARP1 (0.43) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL14734906 | 0.88 | CHRM2 (0.41) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL14735139 | 0.86 | CHRM2 (0.40) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL18890837 | 0.84 | SMARCA2 (0.40) | PSMB5SMARCA2SMARCA4PBRM1 | |
| SCHEMBL14735118 | 0.84 | LTB4R (0.39) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL14735036 | 0.83 | CHRM2 (0.38) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL18863989 | 0.83 | GPR119 (0.44) | KDM4EMAPTPSMB5 | |
| SCHEMBL14735352 | 0.83 | PSMB5 (0.48) | KMT2AKDM4EALDH1A1MAPTGAA | |
| SCHEMBL14734890 | 0.82 | VEGFA (0.48) | VEGFAEGLN1CHRM2CHRM4CHRM1 | |
| SCHEMBL14734978 | 0.82 | MRGPRX4 (0.46) | VEGFAEGLN1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | PIM3, PIM1, PIM2 | VEGFA 3696/4885EGLN1 1995/4885CHRM2 4870/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | VEGFA 2323/4885EGLN1 394/4885CHRM2 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.